SUMMARY -Th e aim of the study was to establish the importance of low molecular weight heparin (LMWH) treatment for good pregnancy outcome in patients with hereditary thrombophilia. Th is retrospective study included 70 patients with inherited thrombophilia who gave birth at Zagreb University Hospital Center in the period from January 2014 to January 2015. Fifty-seven women were treated and 13 women were not treated with LMWH. Perinatal outcome was signifi cantly better in women with hereditary thrombophilia who were treated with heparin during pregnancy as compared with women without LMWH (p=0.006). Regardless of heparin therapy, patients with hereditary thrombophilia alone had a signifi cantly better perinatal outcome as compared with women who, along with hereditary thrombophilia, had a history of habitual abortions (p=0.035) or intrauterine fetal death (p=0.033). Women treated with heparin had better perinatal outcome if they were without a history of recurrent or non-recurrent fetal loss (p=0.088). In the group without LMWH, perinatal outcome was signifi cantly better in women with no history of habitual abortions as compared with women with recurrent miscarriages (p=0.047). Administration of LMWH is justifi ed in women with hereditary thrombophilia and a history of adverse perinatal outcome.
Introduction
Th rombophilias are inherited or acquired conditions that create a hypercoagulable state which predisposes the individual to thromboembolism [1] [2] [3] . Inherited defects related to thrombosis include the G1691A mutation in the factor V gene, the G20210A mutation in the prothrombin gene, the C677T mutation and the A1298C mutation in the methylenetetrahydrofolate reductase (MTHFR) gene, antithrombin III, protein C and protein S defi ciency 4 . Th e most entrenched acquired thrombophilia is the antiphospolipid syndrome, a non-infl ammatory autoimmune disease characterized by the presence of antiphospholipid antibodies. Antiphospholipid syndrome can be either primary or secondary to another autoimmune disease. Th e overall impact of inherited and acquired thrombophilias is low in non-pregnant population and the majority of patients never experience a thrombotic event. During pregnancy, however, the thrombogenic potential of these disorders is enhanced because of the hypercoagulable state produced by normal pregnancy-associated changes with which the mother's body adjusts to pregnancy and later on to childbirth. Such changes occur in the blood fl ow, vascular wall and coagulation factors (increased levels of factors VII, VII, X and von Willebrand's factor, decreased activity levels of protein C and protein S, and increased activity level of fi brinolytic inhibitors) 4 . Whereas in recent years numerous studies have established the association between acquired thrombo-philias and adverse pregnancy outcome [5] [6] [7] , inherited thrombophilia and related complications in pregnancy still remain debatable 8, 9 . Available evidence does not support an association between inherited thrombophilia and preeclampsia, fetal growth restriction, or abruption, and, in turn, it does not support prophylactic anticoagulation to prevent the possible adverse pregnancy outcomes in patients with hereditary thrombophilias 10 . However, adverse medical and obstetric history in patients with inherited thrombophilia requires special caution for good outcome of the current pregnancy.
Th e aim of the study was to establish the role of low molecular weight heparin (LMWH) in patients with inherited thrombophilia for good pregnancy outcome, with special emphasis on the women with adverse obstetric history, and to identify the common types of mutation in the study group.
Patients and Methods
Th is retrospective epidemiological study was conducted at the State Referral Center for Diabetes in Pregnancy, Zagreb University Hospital Center, Zagreb, Croatia, during the period from January 2014 to January 2015. Th e study included 70 patients diagnosed with hereditary thrombophilia. All enrolled patients delivered in our hospital but the majority of them had their regular examinations and treatment provided by their physicians in primary or secondary health care centers. Patients were classifi ed into two groups: 57 women with hereditary thrombophilia that were treated with LMWH and 13 women not treated with LMWH despite the diagnosis of inherited thrombophilia. Patient characteristics including demographics, obstetric and medical history were obtained from patients at the hospital visit and entered in the database. Data on pregnancy outcomes were obtained from the delivery suite database.
Statistical analysis
All statistical analyses were performed using the SPSS for Windows, release 17 (SPSS Inc., Chicago, IL, USA). For quantitative measurements (continuous), the mean and standard deviation was calculated. For qualitative measurements, absolute frequency was calculated and prevalence was expressed as percentage. Th e c 2 -test was used on comparison of qualitative data.
All the variables collected were statistically analyzed and presented descriptively. Inferential statistical analysis aimed to investigate the relationship between the use of LMWH in women with thrombophilic mutations and their perinatal outcome. Th e level of statistical signifi cance was set at p<0.05.
Results
A total of 70 women with inherited thrombophilia who gave birth at the Zagreb University Hospital Center were recruited during the study period. Th e mean age of study patients was 34.2±4 years, range 20-45 years. Th e mean body mass index was 25.7 (range 18-35). Th e minimum number of pregnancies was 1 and maximum 9, with a mean value of 2.9. Th e minimum number of deliveries was 0 and maximum 2, and the mean number of abortions was 1.37 (range 0-7) ( Table 1) . Six (8.5%) women experienced venous thromboembolism before their pregnancy. Th ese pregnant women were found to have a family history of venous thromboembolism, myocardial infarction or stroke in fi rst-degree relatives younger than 50. Th e prevalence of this history was 15.7% (11 patients).
Nine (12.5%) women with inherited thrombophilia had a diagnosis of primary or secondary infertility and six (6.6%) of them conceived using in vitro fertilization (IVF). Six (8.5%) patients had hypertensive disorders such as gestational hypertension and preeclampsia (50% both), and eight (11.4%) women were diagnosed with gestational diabetes (Table 2 ).
All study women had DNA blood tests that confi rmed gene mutations for hereditary thrombophilia. Twenty diff erent combinations of gene mutations were identifi ed (Table 3) .
Given the high prevalence of diff erent types of mutations in the study group, the mutations were classifi ed as isolated (n=27; 38.6%) and combined (n=43; 38.7%) ( Table 4) .
Analysis of medical records found that treatment with heparin was based on obstetric and family history, as well as on the type of mutation for hereditary thrombophilia.
Using Pearson's c 2 -test, we analyzed perinatal outcome in all women with hereditary thrombophilia (Table 5 ), in women with hereditary thrombophilia treated with LMWH (Table 6 ) and in women with hereditary thrombophilia not treated with LMWH (Table 7) . Adverse perinatal outcome such as intrauterine growth restriction (IUGR), intrauterine fetal death (IUFD), placental abruption, abortion and preeclampsia (PE) was observed.
According to study results, patients with hereditary thrombophilia that received LMWH had a significantly better perinatal outcome as compared with the group without LMWH (p=0.006).
Th e abortion rate was lower in the group with LMWH; however, this group had a higher incidence of placental abruption. Th ere were no signifi cant differences according to the type of mutation (isolated and combined) and perinatal outcome (p=0.661).
Regardless of LMWH, women without habitual abortions had a signifi cantly better perinatal outcome as compared with women with recurrent miscarriages (with emphasis on recurrent spontaneous abortion) (p=0.035). Nevertheless, women with no history of adverse perinatal outcome had a signifi cantly better pregnancy outcome as compared with women with a history of IUFD (p=0.033). Th e latter group showed a higher incidence (15.6%) of placental abruption in the observed pregnancy (Table 5 ).
In the group of women with hereditary thrombophilia treated with LMWH, we found no association between the type of mutation (isolated or combined) and perinatal outcome (p=0.636). In the same group, there was no signifi cant diff erence in perinatal outcome between the women with normal pregnancy outcome and those with habitual abortions in previous pregnancies (p=0.398). Although there was no significant diff erence in perinatal outcome between women with normal pregnancy outcome and those with IUFD in previous pregnancies (p=0.088), women with IUFD in previous pregnancies had a higher incidence of placental abruption in the observed pregnancy (15.4%) ( Table 6 ).
In the group of women with hereditary thrombophilia but without LMWH treatment, we found no association between the type of mutation (isolated or combined) and perinatal outcome (p=0.380). Patients with no history of adverse perinatal outcome had a signifi cantly better perinatal outcome than women with a history of recurrent miscarriages (p=0.047). In this group, there was no patient with a history of IUFD. 10 .486 Df 4 P 0.033 HT = hereditary thrombophilia; IUGR = intrauterine growth restriction; PE = preeclampsia; n = number; LMWH = low molecular weight heparin; IUFD = intrauterine fetal death Unfortunately, the number of cases in this group was too small to obtain meaningful data (Table 7) .
Discussion
Th rombophilia in mothers, in addition to natural hemostatic changes in every pregnancy, also changes placental circulation 11, 12 . Th romboses of maternal placenta may cause complications such as preeclampsia and IUGR, as well as more serious complications such as miscarriage, placental abruption and IUFD. Numerous studies have evaluated the correlation between thrombophilia and pathologic perinatal outcome. Even though some retrospective studies argue there is a link between certain mutations (heterozygous factor V Leiden, heterozygous prothrombin gene, protein C and S defi ciency) and missed abortions after 10 weeks of gestation, recurrent miscarriages and IUFD after 20 weeks of gestation, the majority of prospective studies deny this causal connection [13] [14] [15] . Our study included a heterogeneous group of women of diff erent age groups, diff erent family and personal history, and diff erent reasons for genetic testing for hereditary thrombophilia. Diff erent widespread mutations and their combinations found in our geographical area refl ected in our study group, with a predominance of so-called 'mild mutations' such as PAI1 and MTHFR, and a lesser percentage of 'severe mutations' such as factor V Leiden and factor II mutations. Despite the already inveterate opinion that hereditary thrombophilia has a negligible impact on perinatal outcome, women in our study that were administered LMWH had a statistically much better perinatal outcome than women that did not receive this therapy, irrespective of the mutation type (p=0.006). Women treated with heparin experienced a lower percentage of miscarriages; however, more cases of placental abruption were recorded in this group. Furthermore, an unfortunate outcome of previous pregnancies (e.g., recurrent miscarriages, IUFD) also led to worse perinatal outcome of the observed pregnancies. It is important to highlight that all the observed women with hereditary thrombophilia and recurrent miscarriages that were not treated with heparin had a statistically worse perinatal outcome as compared with women who were not treated with heparin either but had unremarkable obstetric history.
Th is study results supported the Royal College of Obstetricians and Gynaecologists Green-top guidelines, clearly stressing the importance of LMWH for better perinatal outcome in pregnant women with he- HT = hereditary thrombophilia; IUGR = intrauterine growth restriction; PE = preeclampsia; n = number; LMWH = low molecular weight heparin; IUFD = intrauterine fetal death reditary thrombophilia and pathologic perinatal outcomes in previous pregnancies, especially recurrent trimester II miscarriages or IUFD 16 . It is concluded that, regardless of the mutation type, hereditary thrombophilia, in addition to complicated obstetric history, requires and justifi es LMWH therapy administration for the purpose of a favorable perinatal outcome. Th is is especially true for patients with a complicated family history.
Th rombophilia is a widespread gene mutation, mostly detected incidentally when one's clinical features are provoked by a state of hypercoagulability, such as pregnancy. Recurrent pathologic outcomes of pregnancies in mutation-carrying women indicate the body's struggle to adjust to the new setting. Numerous contradictory results of various studies on the thrombophilia eff ect on perinatal outcome can be ascribed to small test groups, diff erent diagnostic criteria and predominantly retrospective study design. Studies on greater test groups are needed to clarify the real eff ect of certain mutations on pregnancies. Administration of heparin can help the body fi ght for a better perinatal outcome, especially in women who have already lost the battle in past pregnancies. According to our results, LMWH proved to be the treatment of choice in patients with adverse pregnancy events in which thrombophilic mutations were identifi ed. Cilj ove studije bio je ustanoviti komplikacije trudnoće i važnost primjene niskomolekularnog heparina za poboljšanje perinatalnog ishoda kod trudnica s nasljednom trombofi lijom. Retrospektivno su analizirani podatci 70 trudnica s dokazanom hereditarnom trombofi lijom i urednom ili opterećenom opstetričkom anamnezom koje su porođene u Klinici za ženske bolesti i porođaje u razdoblju od siječnja 2014. do siječnja 2015. Njih 57 liječeno je niskomolekularnim heparinom, dok kod ostalih 13 žena nije provedena antikoagulantna terapija. Ispitanice s nasljednom trombofi lijom koje su tijekom trudnoće uzimale heparinsku terapiju imale su statistički značajno bolji perinatalni ishod u odnosu na ispitanice s nasljednom trombofi lijom bez antikoagulantne terapije (p=0,006). Ispitanice s hereditarnom trombofi lijom i urednom opstetričkom anamnezom imale su statistički značajno bolji perinatalni ishod u odnosu na ispitanice s trombofi lijom i prethodnim habitualnim pobačajima (p=0,035) ili intrauterinom smrti čeda (p=0,033). Ispitanice s hereditarnom trombofi lijom i urednim prethodnim trudnoćama koje su liječene heparinom imale su nešto bolji perinatalni ishod u odnosu na skupinu s trombofi lijom i prethodnim mors fetus in utero kod kojih je također primjenjivana antikoagulantna terapija (p=0,088). U skupini ispitanica s hereditarnom trombofi lijom a bez heparinske terapije, ispitanice bez habitualnih pobačaja u anamnezi imale su statistički značajno bolji perinatalni ishod u odnosu na trudnice s habitualnim pobačajima (p=0,047). Primjena niskomolekularnog heparina za bolji perinatalni ishod opravdana je kod trudnica s nasljednom trombofi lijom i opterećenom opstetričkom anamnezom.
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